Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Comprar returned no results
Showing 61 to 75 of 556 results for compare

  1. Few women use contraception perfectly (that is, exactly in accordance with the product instructions) and consistently. Pregnancy rates during typical use reflect effectiveness of a method among women who use the method incorrectly or inconsistently. Few data are available on typical use of any contraceptive method among women in the UK. Much of the data on contraceptive effectiveness used in the guideline come from clinical trials or surveys undertaken in other countries such as the USA. Large prospective cohort studies are needed to compare the contraceptive effectiveness of LARC methods with non‑LARC methods during typical use in the UK.

    countries such as the USA. Large prospective cohort studies are needed to compare the contraceptive effectiveness of LARC methods with...

    Research recommendation
    Published
    25 October 2019

  2. Nivolumab for previously treated advanced renal cell carcinoma (TA417)

    Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA417

  3. Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)

    Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    10 April 2024
    View recommendations

    Sections for TA964

  4. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for vaginal vault prolapse

    type of treatment: what it involves, the risks and benefits, and how they compare to each other. If the type of surgery you would prefer...

  5. A randomised controlled trial is recommended to compare DyeVert Systems  with standard care. The aim of this research would be to address uncertainties  about whether using DyeVert Systems reduces AKI incidence and rate of renal  replacement therapy after using contrast media. This must include people with  stage 4 chronic kidney disease (with an estimated glomerular filtration rate  [eGFR] under 30 ml/min/1.73 m 2 ), who are at risk of AKI and need elective  coronary or peripheral angiography.

    MTG60/01 Question A randomised controlled trial is recommended to compare DyeVert Systems with standard care. The aim of this research...

    Research recommendation
    Published
    5 November 2021

  6. Community engagement: improving health and wellbeing and reducing health inequalities (NG44)

    This guideline covers community engagement approaches to reduce health inequalities, ensure health and wellbeing initiatives are effective and help local authorities and health bodies meet their statutory obligations.

    NICE guideline
    Published
    4 March 2016
    View recommendations

    Sections for NG44

  7. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

    Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.

    Technology appraisal guidance
    Published
    14 December 2011
    View recommendations

    Sections for TA238

  8. Upadacitinib for treating moderate rheumatoid arthritis (TA744)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    10 November 2021
    View recommendations

    Sections for TA744

  9. Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)

    Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by narcolepsy in adults.

    Technology appraisal guidance
    Published
    5 January 2022
    View recommendations

    Sections for TA758

  10. Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.

    Technology appraisal guidance
    Published
    23 June 2021
    View recommendations

    Sections for TA709

  11. Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments (TA947)

    Evidence-based recommendations on loncastuximab tesirine (Zynlonta) for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments.

    Technology appraisal guidance
    Published
    31 January 2024
    View recommendations

    Sections for TA947

  12. Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults.

    Technology appraisal guidance
    Published
    27 July 2016
    View recommendations

    Sections for TA400

  13. How frequently the remote monitoring devices were modelled as being used substantially affected the cost-effectiveness estimates in the EAG's model (see section 3.9 ). There are many ways the devices could be used in the NHS (see section 3.3 ) and no data was available to compare different approaches. So, it is currently not possible to highlight particular approaches that are likely to be more clinically and cost effective. Centres using the devices should therefore collect data on how often they are used and under what circumstances. For example, regularly in advance of scheduled review appointments, to indicate when such appointments are needed, or targeted to people having issues with symptoms. This will help assess the clinical and cost effectiveness of the different uses of the devices in NHS practice.

    could be used in the NHS (see section 3.3 ) and no data was available to compare different approaches. So, it is currently not possible...

    Research recommendation
    Published
    7 March 2023

  14. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (HTG401)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.

    HealthTech guidance
    Published
    17 February 2016
    View recommendations

    Sections for HTG401

  15. Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)

    Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making

    Evidence summary
    Published
    15 December 2015